The initial contract is for 8 months. Todos has also been granted a priority right to supply the lab with up to 75,000 COVID PCR tests per day in the event the laboratory sees significant additional testing demand.
Under the terms of the agreements, PATHNOVA will be responsible for the further development and commercialization of the Todos Tests in Singapore, and Todos Medical will assist PATHNOVA in commercializing its nasopharyngeal cancer tests through its affiliates in the United States and Singapore.
This funding will enable RetiSpec to accelerate the commercialization of its groundbreaking technology aimed at early detection of Alzheimer's disease.
